From Wikipedia, the free encyclopedia
Belapectin Other names GR-MD-02 Galactoarabino-rhamnogalacturonate
Legal status
α-D -Galacturono-α-D -galacto-β-D -galacto-6-deoxy-α-L - manno-α-L -arabinan, (1→2),(1→3),(1→4)-, methyl ester
CAS Number
UNII
Belapectin (also known as GR-MD-02) is a
galectin-3 inhibitor developed by
Galectin Therapeutics that is in
clinical trials for the treatment of
non-alcoholic steatohepatitis .
[1]
[2]
[3]
[4]
References
^ Mireku, Akosua (26 June 2023).
"NASH drugs race to cross the finish line" . Pharmaceutical Technology . Retrieved 21 October 2023 .
^ Al Attar, Atef; Antaramian, Ani; Noureddin, Mazen (3 April 2021). "Review of galectin-3 inhibitors in the treatment of nonalcoholic steatohepatitis". Expert Review of Clinical Pharmacology . 14 (4): 457–464.
doi :
10.1080/17512433.2021.1894127 .
^ Slack, R.J.; Mills, R.; Mackinnon, A.C. (January 2021).
"The therapeutic potential of galectin-3 inhibition in fibrotic disease" . The International Journal of Biochemistry & Cell Biology . 130 : 105881.
doi :
10.1016/j.biocel.2020.105881 .
^ Tapper, Elliot B.; Ufere, Nneka N.; Huang, Daniel Q.; Loomba, Rohit (May 2022).
"Review article: current and emerging therapies for the management of cirrhosis and its complications" . Alimentary Pharmacology & Therapeutics . 55 (9): 1099–1115.
doi :
10.1111/apt.16831 .
ISSN
0269-2813 .